Stock Analiz

Castle Biosciences Inc. (CSTL) financials: revenue, earnings and cash flow

Fiscal 2018–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Castle Biosciences’s revenue went from $23M in fiscal 2018 to $344M in fiscal 2025, growth of about 47.4% a year.

Net income in fiscal 2025 was -$24M, a net margin of -7.0%; the best year in this period was 2024 with $18M.

Over the twelve months to September 30, 2026, revenue was $377M and net income -$23M.

Free cash flow was $28M in fiscal 2025 and positive in 4 of the 8 years shown.

The diluted share count rose 1421% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2018: $23M20182019: $52M20192020: $63M20202021: $94M20212022: $137M20222023: $220M20232024: $332M20242025: $344M2025$344M
Net income
2018: -$6M20182019: $5M20192020: -$10M20202021: -$31M20212022: -$67M20222023: -$57M20232024: $18M20242025: -$24M2025-$24M
Free cash flow
2018: -$13M20182019: $6M20192020: $5M20202021: -$22M20212022: -$47M20222023: -$19M20232024: $37M20242025: $28M2025$28M
EPS (diluted)
2018: $-5.3320182019: $-0.2120192020: $-0.5420202021: $-1.2420212022: $-2.5820222023: $-2.1420232024: $0.6220242025: $-0.832025$-0.83

Income statement

Fiscal yearTTM20252024202320222021202020192018
Revenue$377M$344M$332M$220M$137M$94M$63M$52M$23M
Gross profit$291M$273M$272M$175M$105M$78M$53M$45M$17M
Operating income-$28M-$43M$9M-$68M-$73M-$40M-$7M$7M-$4M
Net income-$23M-$24M$18M-$57M-$67M-$31M-$10M$5M-$6M
EPS (diluted)$-0.76$-0.83$0.62$-2.14$-2.58$-1.24$-0.54$-0.21$-5.33
R&D$58M$52M$52M$54M$45M$30M$13M$7M$5M
Revenue growth—+3.7%+51.1%+60.4%+45.6%+50.2%+20.8%+127.6%—

Cash flow

Fiscal yearTTM20252024202320222021202020192018
Operating cash flow$40M$64M$65M-$6M-$42M-$19M$10M$7M-$12M
Capital spending-$36M-$36M-$28M-$14M-$6M-$3M-$5M-$937000-$277000
Free cash flow$4M$28M$37M-$19M-$47M-$22M$5M$6M-$13M
Dividends paid—$0$0$0$0$0$0$0$0
Buybacks—————————
Stock-based pay$44M$46M$50M$51M$36M$22M$8M$1M$294000

Balance sheet

Fiscal yearTTM20252024202320222021202020192018
Cash—$300M$293M$243M$259M$330M$410M$99M$4M
Debt—$37M$26M$15M$13M$8M$0$27M$24M
Equity—$471M$456M$391M$399M$412M$416M$85M-$57M
Total assets—$579M$531M$453M$447M$463M$439M$120M$22M
Shares (diluted)31M29M29M27M26M25M19M9M2M

Margins and returns

Fiscal yearTTM20252024202320222021202020192018
Gross margin77.1%79.4%81.9%79.5%76.6%83.2%84.5%85.9%76.8%
Operating margin-7.4%-12.4%2.6%-30.9%-53.2%-42.6%-10.4%14.1%-16.8%
Net margin-6.1%-7.0%5.5%-26.2%-49.0%-33.3%-16.4%10.2%-27.9%
FCF margin1.1%8.2%11.0%-8.8%-34.5%-23.9%8.2%11.7%-55.2%
ROIC—-6.7%1.4%-13.2%-14.0%-7.5%-1.2%5.2%—
ROE—-5.1%4.0%-14.7%-16.8%-7.6%-2.5%6.2%11.3%

Frequently asked questions

What is Castle Biosciences’s annual revenue?

$344M in fiscal 2025 and $377M over the twelve months to September 30, 2026.

How much profit does Castle Biosciences make?

Net income was -$24M in fiscal 2025 (net margin -7.0%).

Is Castle Biosciences’s revenue growing?

Yes: revenue rose 3.7% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.